€1.94
Your prediction
Financial data and news for Cardiol Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Cardiol Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Toronto, ON – June 25, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
- Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis pain
- CardiolRx™ also shown to reduce inflammation in patients
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
- Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients with recurrent pericarditis, with topline results expected in Q2 2024
-
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Topline Results Expected in Q2 2024
This is a Designated News Release.
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”),
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
This is a Designated News Release.
Toronto, ON – February 15, 2024 –